Details

Autor(en) / Beteiligte

• Liu, Lu
• Xiang, Yujiao
• Shao, Linlin
• Yuan, Chenglu
• Song, Xiaofeng
• Sun, Meng
• Liu, Yanfeng
• Zhang, Xianlei
• Du, Shenghong
• Hou, Ming
• Peng, Jun
• Shi, Yan

Titel

E3 ubiquitin ligase casitas B-lineage lymphoma-b modulates T-cell anergic resistance via phosphoinositide 3-kinase signaling in patients with immune thrombocytopenia

Ist Teil von

• Journal of thrombosis and haemostasis, 2024-04, Vol.22 (4), p.1202-1214

Ort / Verlag

England: Elsevier Inc

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• The E3 ubiquitin ligase casitas B-lineage lymphoma-b (CBLB) is a newly identified component of the ubiquitin-dependent protein degradation system and is considered an important negative regulator of immune cells. CBLB is essential for establishing a threshold of T-cell activation and regulating peripheral T-cell tolerance through various mechanisms. However, the involvement of CBLB in the pathogenesis of immune thrombocytopenia (ITP) is unknown. We aimed to investigate the expression and role of CBLB in CD4+ T cells obtained from patients with ITP through quantitative proteomics analyses. CD4+ T cells were transfected with adenoviral vectors overexpressing CBLB to clarify the effect of CBLB on anergic induction of T cells in patients with ITP. DNA methylation levels of the CBLB promoter and 5′ untranslated region (UTR) in patient-derived CD4+ T cells were detected via MassARRAY EpiTYPER assay (Agena Bioscience). CD4+ T cells from patients with ITP showed resistance to anergic induction, highly activated phosphoinositide 3-kinase–protein kinase B (AKT) signaling, decreased CBLB expression, and 5′ UTR hypermethylation of CBLB. CBLB overexpression in T cells effectively attenuated the elevated phosphorylated protein kinase B level and resistance to anergy. Low-dose decitabine treatment led to significantly elevated levels of CBLB expression in CD4+ T cells from 7 patients showing a partial or complete response. These results indicate that the 5′ UTR hypermethylation of CBLB in CD4+ T cells induces resistance to T-cell anergy in ITP. Thus, the upregulation of CBLB expression by low-dose decitabine treatment may represent a potential therapeutic approach to ITP.